Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer

OBJECTIVES:

Primary

• Investigate the changes in Ki67 and PCNA in postmenopausal women with estrogen receptor-positive (ER+) breast cancer after 4 months of treatment with letrozole vs tamoxifen citrate.

Secondary

• Compare the response after 4 months of therapy.
• Define the resistant forms of cancer in patients treated with these regimens.
• Define the molecular signature predictive of sensitivity or resistance to ER+ breast adenocarcinoma by gene and serum protein profiling.
• Search for serum protein profiles predictive of recurrence-free interval.

OUTLINE: Patients are randomized into 1 of 2 intervention arms.

• Arm I: Patients receive oral letrozole once daily for 16 weeks.
• Arm II: Patients receive oral tamoxifen citrate once daily for 16 weeks. Patients in both arms then undergo surgery.

Blood and tumor tissue samples are collected at baseline and after completion of neoadjuvant therapy for changes in Ki67 and PCNA and serum protein profiling analysis.

After completion of study therapy, patients are followed up every 6 months for 3 years, and then once a year for 5 years.

DISEASE CHARACTERISTICS:

• Histologically confirmed invasive breast adenocarcinoma

• Clinically T2 tumor and/or > 1 cm by echography
• Estrogen receptor (ER)-positive and > 10% of the tumor cells positive

• No ER-negative disease
• No prior breast cancer
• No metastatic or inflammatory breast adenocarcinoma

PATIENT CHARACTERISTICS:

• Postmenopausal
• No cardiac function that could contraindicate surgery or medical treatment (e.g., radiotherapy and/or chemotherapy)
• No prior malignancies within the past 5 years except for nonmelanoma skin cancer or carcinoma in situ of the cervix
• No mental incapacitation that would preclude consent
• No contraindication to tamoxifen citrate or letrozole

PRIOR CONCURRENT THERAPY:

• More than 8 days since prior hormone-replacement therapy or other treatment (i.e., phytoestrogen) for menopause
• No concurrent therapy that would modify the expression of the genes regulated by estrogen
• No concurrent participation in another clinical study